Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness.
about
Applications of CYP450 testing in the clinical settingPharmacogenetics of antipsychotic adverse effects: Case studies and a literature review for cliniciansMolecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugsCombinatorial Versus Individual Gene Pharmacogenomic Testing in Mental Health: A Perspective on Context and Implications on Clinical UtilityThe potential utility of pharmacogenetic testing in psychiatryPharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug responseA Model Based Cost-Effectiveness Analysis of Routine Genotyping for CYP2D6 among Older, Depressed Inpatients Starting Nortriptyline PharmacotherapyPharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment.The challenge of integrating genetic medicine into primary care.Drug-metabolizing enzyme genotypes and aggressive behavior treatment response in hospitalized pediatric psychiatric patients.Science, medicine, and the future: Pharmacogenetics.The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.Cytochrome P450 polymorphisms and response to antipsychotic therapy.Pharmacogenomics: the future of drug therapy.Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: a retrospective study.The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants.Pharmacogenetics - five decades of therapeutic lessons from genetic diversity.Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature.A systematic review of cost-effectiveness analyses of pharmacogenomic interventions.A Naturalistic Study of the Effectiveness of Pharmacogenetic Testing to Guide Treatment in Psychiatric Patients With Mood and Anxiety Disorders.Genetics and psychopharmacology: prospects for individualized treatment.Pharmacogenomics in cardiovascular disease: the role of single nucleotide polymorphisms in improving drug therapy.Pharmacogenetics in mood disorder.AmpliChip CYP450 test: personalized medicine has arrived in psychiatry.Application of microarray technology in psychotropic drug trials.Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants.Drug-Induced Liver Injury during Antidepressant Treatment: Results of AMSP, a Drug Surveillance ProgramCultural aspects of major mental disorders: a critical review from an Indian perspectiveGenelex Corporation.Frequencies of Functional Polymorphisms in Three Pharmacokinetic Genes of Clinical Interest within the Admixed Puerto Rican PopulationComposite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients.Implementation of CYP2D6 genotyping in psychiatry.Clinical applications of CYP genotyping in psychiatry.Polymorphism in CYP2D6 and CYP2C19, members of the cytochrome P450 mixed-function oxidase system, in the metabolism of psychotropic drugs.The clinical validity and utility of combinatorial pharmacogenomics: Enhancing patient outcomes.Pharmacogenetics of neurological and psychiatric diseases at older age: has the time come?Pharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies.Relationship between cytochrome P450 polymorphisms and prescribed medication in elderly haemodialysis patients.Patient preferences for pharmacogenetic screening in depression.Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics.
P2860
Q24621760-F85FEB47-6579-4D68-8A80-087B2D084EF0Q24657338-EE8EE851-CBEC-4C35-9067-0CCDE94C1C20Q24683013-EBE5D8C4-1C0F-423C-8695-EE5102AC5238Q26775813-E5CF73E1-8EAE-420B-A3D9-7FAB3B679A3DQ28084874-8E02D408-1B4D-4367-A426-B7A7C29F4EB5Q28252209-6A833414-8C88-4813-977A-FE0D455555EDQ28468503-75BA8BA8-3F62-4B91-9B06-3D5B48328164Q31144283-E5EF4153-B805-4523-A0BA-DDB69A716886Q33805196-16752072-A506-49E8-BD4C-5141140398A8Q33819922-95E07FD9-236D-445F-82E9-7373D2775046Q33884661-5A9F4FBB-7959-4989-97CA-FDF21E5E37F7Q34537662-FF0DB4A9-861D-47A1-988F-51212767F67CQ34612118-4FEFEC90-C4C4-406C-AB8C-6EF867C16B0DQ34952587-21E271F9-7FAD-42BC-AC1C-BE167C2D0B65Q35126127-72C02311-FE49-46B1-894D-C80C858CCCFEQ35236618-202D40E2-95C0-4943-9F26-7BBB53DB9449Q35889619-D2C542EC-52D0-4345-B001-CDD0E7EDF3F9Q35890606-6C8BC6ED-FAA2-42BF-AF9A-84CCEC568904Q35976416-481AB0D2-F0F2-46F7-AFED-35C8ADA1A66BQ36028264-D3DFAB6F-B9D3-42B7-B925-5FA3D017C501Q36206096-DD54F6A6-5534-4757-A72A-8B6632E43313Q36326202-5E3C7BB7-C470-4E6C-AF7C-5C36D3DC2888Q36460262-99EB7E61-4F77-4399-B91B-0711F10C22C0Q36481089-3348E1C6-A3C0-4309-862B-78CDCD280E1DQ36511697-E3690026-8521-462B-9597-A76B5A9395FEQ36536465-FA8C233C-E123-4506-822D-C3CFC64FAABEQ36852416-A9B97E3C-4487-4A5A-AA65-67440669E2EEQ36869325-BF089041-0DC8-47C1-96E1-42B285DDBF76Q37126673-F16A0169-9044-468A-ADF4-35357010CCB4Q37162200-14E0E1EE-F408-485A-A9EB-803095FCB311Q37278456-D5A80443-C6B1-458D-B73D-BD5F3441EECBQ37538787-28524519-1F5C-467D-9783-AE11DD5F807CQ38247063-2206DDA0-9E04-4F0F-B651-5F9288F31351Q38258243-AE31B534-D4DB-4ABF-9BAC-4800E29F9D5AQ38283667-E4F1F9BE-3475-4D73-9F7B-BBAF6A9F1293Q38975693-A8A59862-E824-4A41-9913-A9E4709A989DQ38983579-B613C050-F3BD-4029-9385-61A43E9125BAQ39295178-E347BAC4-DA53-41D1-9D85-3EC1AF734668Q39324637-00BB04E6-63B9-411A-99EA-81C3760DCAA0Q39334142-D8D92D0D-94AB-4386-BFD8-741D3A03A488
P2860
Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness.
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Extension of a pilot study: im ...... ed with severe mental illness.
@ast
Extension of a pilot study: im ...... ed with severe mental illness.
@en
type
label
Extension of a pilot study: im ...... ed with severe mental illness.
@ast
Extension of a pilot study: im ...... ed with severe mental illness.
@en
prefLabel
Extension of a pilot study: im ...... ed with severe mental illness.
@ast
Extension of a pilot study: im ...... ed with severe mental illness.
@en
P2093
P1476
Extension of a pilot study: im ...... ted with severe mental illness
@en
P2093
J Barnhill
P J Wedlund
P304
P356
10.1097/00004714-200004000-00019
P407
P50
P577
2000-04-01T00:00:00Z